290 related articles for article (PubMed ID: 25045435)
1. Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer.
Woopen H; Pietzner K; Richter R; Fotopoulou C; Joens T; Braicu EI; Mellstedt H; Mahner S; Lindhofer H; Darb-Esfahani S; Denkert C; Sehouli J
J Gynecol Oncol; 2014 Jul; 25(3):221-8. PubMed ID: 25045435
[TBL] [Abstract][Full Text] [Related]
2. Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.
Pietzner K; Woopen H; Richter R; Joens T; Braicu EI; Dimitrova D; Mellstedt H; Darb-Esfahani S; Denkert C; Lindhofer H; Fotopoulou C; Sehouli J
Int J Gynecol Cancer; 2013 Jun; 23(5):797-802. PubMed ID: 23694980
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer.
Tas F; Karabulut S; Serilmez M; Ciftci R; Duranyildiz D
Tumour Biol; 2014 Apr; 35(4):3095-102. PubMed ID: 24307621
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients.
Lee M
J Gynecol Oncol; 2014 Oct; 25(4):352-4. PubMed ID: 25310035
[No Abstract] [Full Text] [Related]
6. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
8. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients.
Battista MJ; Cotarelo C; Jakobi S; Steetskamp J; Makris G; Sicking I; Weyer V; Schmidt M
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1097-102. PubMed ID: 24728493
[TBL] [Abstract][Full Text] [Related]
11. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.
Xu Y; Wang C; Zhang Y; Jia L; Huang J
Sci Rep; 2015 Jul; 5():12104. PubMed ID: 26175056
[TBL] [Abstract][Full Text] [Related]
13. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
[TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
16. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
17. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
Bamias A; Sotiropoulou M; Zagouri F; Trachana P; Sakellariou K; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Eur J Cancer; 2012 Jul; 48(10):1476-83. PubMed ID: 22047635
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.
Spizzo G; Went P; Dirnhofer S; Obrist P; Moch H; Baeuerle PA; Mueller-Holzner E; Marth C; Gastl G; Zeimet AG
Gynecol Oncol; 2006 Nov; 103(2):483-8. PubMed ID: 16678891
[TBL] [Abstract][Full Text] [Related]
19. Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer.
Frielink LM; Pijlman BM; Ezendam NP; Pijnenborg JM
Chemotherapy; 2016; 61(6):287-94. PubMed ID: 27074010
[TBL] [Abstract][Full Text] [Related]
20. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
Pylväs-Eerola M; Karihtala P; Puistola U
BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
